Clinical trials: Stomach Disorders
Laryngomalacia, Gastro Esophageal Reflux
Initiation of Acid Suppression Therapy Prospective Outcomes for Laryngomalacia
Laryngomalacia (LM) is the most common cause of stridor in infants. Symptoms of gastroesophageal reflux (GER) are often seen in the setting of LM; therefore, acid suppression therapy (AST) has been empirically used in the…
- Trial name
- NCT04614974
- Testing
- Famotidine, Speech Language Therapy
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Reema Padia
Gastroparesis
Safety, PK and Efficacy of PCS12852 on Gastric Emptying Rate in Patients With Moderate to Severe Gastroparesis
This is a randomized, double-blind, placebo-controlled study that will compare the effect of 2 different dosage regimens of PCS12852 on gastric emptying time to placebo in both idiopathic gastroparesis (IG) and diabetic…
- Trial name
- MOMENTUM (NCT05270460)
- Testing
- PCS12852
- Where
- 9 sites in United States
- Volunteers
- 25 people
- Sponsor
- Processa Pharmaceuticals
Obesity
Use of Radiofrequency Ablation for RGB Salvage
The present study will assess the feasibility of using endoscopic radiofrequency ablation (RFA) to treat the gastric pouch and stoma with the intent to cause tissue contraction and decreased compliance after a failed Roux-en-Y…
- Trial name
- NCT01910688
- Testing
- RFA treatment
- Where
- 2 sites in United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Medtronic - MITG
Gastric or Duodenal Ulcers
Special Drug Use Surveillance of Vonoprazan for "Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Low-dose Aspirin: Long-term Use"
The purpose of this survey is to investigate the safety and effectiveness of long-term administration of vonoprazan tablets for up to 12 months in the routine clinical setting in patients receiving low-dose aspirin.
- Trial name
- NCT03214094
- Testing
- Vonoprazan
- Where
- Japan
- Volunteers
- 1,119 people
- Sponsor
- Takeda
Breast Neoplasms, Stomach Neoplasms
Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer.
The aim of the study is to determine the Maximum Tolerated Dose (MTD) of afatinib in combination with 3-weekly trastuzumab in HER2 overexpressing cancer and to assess the efficacy of afatinib given at the MTD dosage, with…
- Trial name
- NCT01649271
- Testing
- Herceptin, afatinib, trastuzumab
- Where
- 3 sites in France
- Volunteers
- 13 people
- Sponsor
- Boehringer Ingelheim
Refractory Reflux Esophagitis
Compare D961H 20 mg Bid and 20 mg qd in Patients With Refractory Reflux Esophagitis (Inflammation of Lower Esophagus)
This is a phase 3 multicentre, randomised, double-blind, parallel-group, comparative study to evaluate the efficacy of esomeprazole (D961H) 20 mg twice daily and esomeprazole (D961H) 20 mg once daily in patients (in the form of…
- Trial name
- NCT01669811
- Testing
- Esomeprazole (D961H) twice daily, Esomeprazole (D961H) once daily
- Where
- 63 sites in Japan
- Volunteers
- 1,398 people
- Sponsor
- AstraZeneca
Dyspepsia and Other Specified Disorders of Function of Stomach
Functional Dyspepsia Treatment Trial
Functional dyspepsia is a common gastrointestinal disorder. Symptoms can include stomach pain or discomfort, bloating, fullness after eating meals, and nausea.
- Trial name
- FDTT (NCT00248651)
- Testing
- Amitriptyline, Escitalopram
- Where
- 8 sites in United States, Canada
- Volunteers
- 292 people
- Sponsor
- Mayo Clinic
Gastroparesis
Placebo Controlled Trial of Botulinum Toxin for Gastroparesis
It is hypothesized that in some patients with gastroparesis increased pyloric tone may be a contributing feature. Botox relaxes the pylorus so that food can empty the stomach more rapidly.
- Trial name
- NCT00372970
- Testing
- Botulinum toxin A
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Temple University
Gastric Adenocarcinoma, Gastroesophageal Adenocarcinoma
Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma
Cabazitaxel will be administered 20 mg/m2 IV over 1 hour every 3 weeks, as is the standard administration dose and schedule. This application is a non-labeled indication for cabazitaxel and will inform future drug development in…
- Conditions
- Gastric Adenocarcinoma, Gastroesophageal Adenocarcinoma, Distal Esophageal Adenocarcinoma
- Trial name
- NCT01757171
- Testing
- Cabazitaxel
- Where
- 5 sites in United States
- Volunteers
- 85 people
- Sponsor
- Weill Medical College of Cornell University
Type 2 Diabetes, Obesity
Vagal Nerve Stimulation and Glucose Metabolism
The overall aim of this application is to determine the mechanism(s) by which common bariatric surgical procedures alter carbohydrate metabolism.
- Conditions
- Type 2 Diabetes, Obesity, Gastric Emptying
- Trial name
- NCT01117311
- Testing
- VNB on, VNB off
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Mayo Clinic
Morbid Obesity, Postoperative Pain
Patients-Controlled Epidural Analgesia After Gastric Bypass for Morbid Obesity Using Morphine-Levobupivacaine Regimens
Adequate postoperative analgesia can facilitate recovery following gastric bypass surgery for morbid obesity. The efficacy and safety of intravenous patient - controlled analgesia has been studied, but up to date no data are…
- Conditions
- Morbid Obesity, Postoperative Pain, Postoperative Bowel Function, Postoperative Ambulation
- Trial name
- NCT01249872
- Testing
- GROUP A : 0 mg MORPHINE-0.1% LEVOBUPIVACAINE, GROUP B : 1 mg MORPHINE- 0.1% LEVOBUPIVACAINE, GROUP C : 2 mg MORPHINE-0.1% LEVOBUPIVACAINE
- Where
- Greece
- Volunteers
- 96 people
- Sponsor
- University of Patras
Morbid Obesity
Laparoscopic Adjustable Gastric Banding in Adolescents
This study is to determine if the Lap-band system is safe and effective for use in morbidly obese adolescents.
- Trial name
- NCT01619488
- Testing
- Adjustable Gastric Band
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Kirk Reichard
Advanced Gastric Cancer
Capecitabine and Cisplatin (XP)+Sorafenib in Advanced Gastric Cancer (AGC): Sorafenib+XP
There is strong scientific rationale for exploring the role of sorafenib with capecitabine and cisplatin (XP) in AGC. XP is a new standard of care in AGC and sorafenib is a novel signal transduction inhibitor that prevents tumor…
- Trial name
- NCT00565370
- Testing
- Capecitabine, Cisplatin, Sorafenib
- Where
- South Korea
- Volunteers
- 22 people
- Sponsor
- Asan Medical Center
Hypoglycemia, Evidence of Previous Gastric Surgery
Pramlintide (Symlin) for the Treatment of Hypoglycemia Following Gastric Bypass Surgery
The purpose of this study is to determine whether pramlintide (Symlin) will help to reduce the frequency and severity of hypoglycemia in individuals who have had gastric bypass surgery.
- Trial name
- NCT01841359
- Testing
- Pramlintide
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Joslin Diabetes Center
Gastric Ulcer, Duodenal Ulcer, Acute Stress Gastritis, and Acute Gastric Mucosal Lesions
Lansoprazole Intravenous 30 mg Specified Drug-use Survey [Hemostatic Effect/Rebleeding Rate]
The purpose of this survey is to evaluate the safety (i.e., frequency of adverse events) and efficacy (i.e., hemostatic effect, rate of rebleeding after confirmation of hemostasis) of administration of lansoprazole intravenous 30…
- Trial name
- NCT02151786
- Testing
- Lansoprazole
- Volunteers
- 1,120 people
- Sponsor
- Takeda
Gastroparesis, Gastroesophageal Reflux
Domperidone for Gastroparesis in Solid Organ Transplantation
The purpose of this study is to examine the clinical response to domperidone in solid organ transplant recipients with gastroparesis.
- Trial name
- NCT00552422
- Testing
- domperidone
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- David J. Lederer, M.D.
Esophageal Cancer, Gastric Cancer
FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer
Anti-angiogenic therapy is a proven therapeutic target in refractory gastric and gastroesophageal junction adenocarcinoma. This trial assessed whether the addition of a high affinity angiogenesis inhibitor, ziv-aflibercept, could…
- Trial name
- NCT01747551
- Testing
- Oxaliplatin, Leucovorin, Fluorouracil
- Where
- 2 sites in United States
- Volunteers
- 64 people
- Sponsor
- Dana-Farber Cancer Institute
Gastric Cancer
Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With TS-1+Cisplatin or TS-1+Oxaliplatin as First Line Chemotherapy in Gastric Cancer (MK-3475-659/KEYNOTE-659)
The purpose of this study is to estimate objective response rates (ORRs) of pembrolizumab + oxaliplatin + TS-1 and pembrolizumab + cisplatin + TS-1, as first-line treatment for gastric cancer in programmed death-ligand 1 (PD-L1)…
- Trial name
- NCT03382600
- Testing
- Pembrolizumab, Oxaliplatin, TS-1
- Where
- 25 sites in Japan
- Volunteers
- 100 people
- Sponsor
- Merck Sharp & Dohme LLC
Gastric Cancer, Peritoneal Carcinomatosis
Randomized Controlled Trial to Prevent Peritoneal Seeding in Gastric Cancer
Randomized Controlled Trial to Prevent Peritoneal Seeding in Gastric Cancer
- Trial name
- HIPECStomach (NCT01683864)
- Testing
- positive cytology with HIPEC
- Where
- Germany
- Volunteers
- 3 people
- Sponsor
- University Hospital Tuebingen
Gastric Adenocarcinoma, Esophageal Cancer
Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer
The primary objective in Phase I is to evaluate the safety and tolerability of sacituzumab govitecan-hziy (SG) as a single agent administered in 21-day treatment cycles in previously treated participants with advanced epithelial…
- Conditions
- Gastric Adenocarcinoma, Esophageal Cancer, Hepatocellular Carcinoma, Non-small Cell Lung Cancer
- Trial name
- NCT01631552
- Testing
- Sacituzumab Govitecan-hziy (SG)
- Where
- 12 sites in United States
- Volunteers
- 515 people
- Sponsor
- Gilead Sciences